Taro Sues Suven To Block Generic Lice Treatment

Law360, New York (May 3, 2011, 1:24 PM EDT) -- Taro Pharmaceuticals North America Inc. filed suit against Suven Life Sciences Ltd. in New Jersey federal court Thursday in an effort to keep it from producing a generic version of head lice treatment Ovide.

Taro claims that India-based Suven's abbreviated new drug application seeking approval from the U.S. Food and Drug Administration to sell its own malathion lotion infringes Taro's patent for the lice killer, which the company markets as Ovide.

The patent-in-suit, U.S. Patent Number 7,560,445, covers pharmaceutical grade malathion, a process for preparing highly...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.